Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribobio-B (06938), has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. to develop innovative siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1] Group 1: Financial Aspects - Ribobio-B's stock price increased by 13.65%, reaching HKD 79.95, with a trading volume of HKD 6.4582 million [1] - The agreement includes an upfront payment of USD 60 million to Ribobio-B, with potential total payments of up to USD 4.4 billion contingent on achieving various clinical development, regulatory approval, and commercial sales milestones [1] Group 2: Development and Collaboration - The collaboration will leverage Ribobio-B's proprietary liver-targeting RiboGalSTAR platform to jointly develop six siRNA therapies for MASH [1] - Ribobio-B grants Madrigal exclusive global rights for the research, production, and commercialization of multiple single-target and dual-target clinical-stage siRNA assets in the MASH field [1]
瑞博生物-B涨超13% 与Madrigal达成44亿美元全球独家许可协议